Bui-Nguyen B, Italiano A, Delva F, Toulmond M
Institut Bergonié, Département d'oncologie médicale, 229, cours de l'Argonne, 33076 Bordeaux cedex, France.
Bull Cancer. 2010 Jun;97(6):673-8. doi: 10.1684/bdc.2010.1114.
The main progress in the management of soft tissue sarcomas have been obtained in the field of local control. Although the main evolutive, vital, risk of these diseases is metastatic dissemination, efficacy of adjuvant chemotherapy remains a controversial issue. Thus, adjuvant chemotherapy cannot be considered as a standard for any situation. The last results of clinical trials, meta-analysis and population studies are presented and discussed in this article. New therapeutic strategies are to be developed to prevent metastases in soft tissue sarcomas. This needs a better understanding of the biology of those tumors, of metastases risk factors and of the determinants of systemic therapies efficacy in these tumors.
软组织肉瘤治疗的主要进展体现在局部控制领域。尽管这些疾病主要的进展、关键风险是转移扩散，但辅助化疗的疗效仍是一个有争议的问题。因此，辅助化疗不能被视为适用于任何情况的标准治疗方法。本文展示并讨论了临床试验、荟萃分析和人群研究的最新结果。需要开发新的治疗策略来预防软组织肉瘤的转移。这需要更好地了解这些肿瘤的生物学特性、转移风险因素以及这些肿瘤全身治疗疗效的决定因素。
